AAM Calls For FTC Scrutiny Of Pharmacy Benefit Manager Practices
PBMs Often Fail To Encourage Generic And Biosimilar Use
Pharmacy benefit managers often fail to encourage the use of generic and biosimilar medications and in fact undermine patient access to these more affordable drugs, the Association for Accessible Medicines has told the US Federal Trade Commission.
You may also be interested in...
With formal study still stalled, the information collection will enable FTC to examine a ‘wide array’ of pharmacy benefit manager business practices impacting patients, payers and pharmacies.
The latest AAM-sponsored study from Avalere Health has found that, for the third year in the row, an increasing percentage of generic drugs are being placed on higher-cost non-generic tiers, even as the overall price of generic drugs decreases.
Agencies seek public comment on how they can modernize merger guidelines to enforce antitrust laws. List of questions, including what types of evidence show that a merger could reduce competition, indicate pharma and other mergers will face greater scrutiny.